For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 7,407 | |||
| General, administrative and other | 9,242 | |||
| Total operating expenses | 16,649 | |||
| Loss from operations | -16,649 | |||
| Change in fair value of warrant liability | 0 | |||
| Change in fair value of forward contract liability | 0 | |||
| Change in fair value of sepa put option liability | 352 | |||
| Change in fair value of convertible debt | -1,773 | |||
| Commitment fee expenses | 0 | |||
| Placement agent and tail fee expenses | 0 | |||
| Other income/(expense) | -619 | |||
| Gain on termination of warrant and commitment fee liabilities | 0 | |||
| Interest income | 247 | |||
| Interest expense | 204 | |||
| Total other income/(expense) | -1,997 | |||
| Net loss | -18,646 | |||
| Basic EPS | -0.42 | |||
| Diluted EPS | -0.42 | |||
| Basic Average Shares | 44,660,518 | |||
| Diluted Average Shares | 44,660,518 | |||
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)